JCR Pharmaceuticals: Notice of Organizational and Personnel Changes

Press release

July 27, 2022

JCR Pharmaceuticals Co., Ltd.


Notice of Organizational and Personnel Changes

July 27, 2022 — JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) today announced the following organizational and personnel changes.

1. Organizational changes

The Production Department will be reorganized by function, moving to an organization around a very advanced specialization axis. This reorganization will manage simplified tasks and build a robust manufacturing system to support globalization.

The production strategy unit will be created to consolidate the supply planning and management functions within the Production Division.

The production management department will be reorganized into production management unit undertake appropriate manufacturing planning, purchasing, negotiation and storage operations. In addition, following the review of the functions of the Logistics Management Department, its functions will be absorbed into the Production Division.

The newly established the HSE* & Maintenance Unit will fully integrate manufacturing control functions, such as occupational safety and health, facility maintenance and other operations, of each unit with the aim of aligning manufacturing management operations and strengthening the ‘organization. Health, Safety, Environments

To enable flexible manufacturing, the existing Active Pharmaceutical Ingredient (API) and Formulation units will be reorganized to a similar function and the following three manufacturing units will be newly created:

Formulation unit will have the function of manufacturing the formulation, single-use technology unit will have the function of making APIs with single-use technology, and central production unit will have the function of making long-term listed products.

2. Personnel changes

Last name

New title

Current Organization

Nobuyuki Tanaka

Director, Production Strategy

Director, Production Division

Unit, Production Division

Kiyoji Onishi

Director, Production

Director, Production Management

Management Unit, Production

Department, Production Division


Kenji Isokawa

Director, HSE & Maintenance

Director, Seishin Production Unit,

Unit, Production Division

Production Department

Yasushi Zenitani

Director, Single Use Technology

Director, Kobe API Unit,

Unit, Production Division

Production Department

Yukihiro Kuromoto

Director, Commodity Unit,

Director, Murotani API Unit,

Production Department

Production Department

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is an international specialty pharmaceutical company redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build on our 47-year legacy in Japan while expanding our global footprint in the United States, Europe and Latin America. We improve the lives of patients by applying our scientific expertise and unique technologies to research, develop and deliver next-generation therapies. Our products approved in Japan include therapies for the treatment of growth disorders, Fabry disease, acute graft versus host disease and renal anemia. Our investigational products in development around the world are aimed at treating rare diseases, including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand possibilities for patients while accelerating medical progress globally. Our core values ​​- reliability, trust and persistence – benefit all of our stakeholders, including employees, partners and patients. Together we soar. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Caution Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are beyond our control. Forward-looking statements often contain words such as “believe”, “estimate”, “anticipate”, “intend”, “plan”, “will”, “would”, “target” and similar references to future periods. All forward-looking statements regarding our plans, prospects, strategy and future activities, financial performance and financial condition are based on judgments made from information available to us at the time. Factors or events that could cause our actual results to differ materially from those expressed in our forward-looking statements include, but are not limited to, deterioration in economic conditions, a change in the legal or governmental system, a delay in the launch of a new product, an impact on the prices and product strategies of competitors, a decline in the ability to market our products, difficulties or delays in manufacturing, a violation of our intellectual property rights, a decision adverse litigation in a major lawsuit and regulatory actions.

This document contains information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Further, it is intended to provide information about our company and our business and not to solicit investment in any securities issued by us.

Except as required by law, we undertake no obligation to publicly update these forward-looking statements or to update factors that could cause actual results to differ materially, even if new information becomes available at coming.

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Business communication

[email protected]



JCR Pharmaceuticals Co.Ltd. published this content on July 27, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on July 27, 2022 07:11:02 UTC.

Public now 2022


Sales 2023 43,068M
2023 net income 9,907M
72.2 million
72.2 million
Net cash 2023 22,230M
162 million
162 million
PER 2023 ratio 33.4x
2023 return 0.74%
Capitalization 330B
EV / Sales 2023 7.16x
EV / Sales 2024 7.14x
# of employees 816
Floating 47.3%


Duration :

Period :

JCR Pharmaceuticals Co., Ltd.  Technical Analysis Chart |  MarketScreener

Trending Technical Analysis JCR PHARMACEUTICALS CO., LTD.

Short term Middle term Long term
Tendencies Bullish Bullish Neutral

Evolution of the income statement


To buy

Medium consensus SURPASS
Number of analysts ten
Last closing price ¥2,670.00
Average target price ¥3,002.00
Average Spread / Target 12.4%

Aubrey L. Morgan